Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from and Astellas and Seattle Genetics, Genentech and Merck Sharp & Dohme Corp.
Shifting Paradigms in Bladder Cancer: How Immunotherapeutic Strategies Are Changing Courses of Care
Thursday, February 14, 2019
7:00PM – 9:00PM
Dinner and registration: 6:30 PM – 7:00 PM
San Francisco Marriott Marquis
Salon 8 Yerba Buena Ballroom, Lower B2 Level
780 Mission Street San Francisco, CA 94103
Until recently, there had been little progress to improve outcomes in the setting of advanced bladder cancer. The emergence of immuno-oncology strategies has improved outcomes in the management of a number of solid tumors; this includes the treatment of bladder cancer, for which the development of checkpoint inhibitors has been a focal point of novel drug development in multiple settings.
With the recent approval of several immuno-oncology agents as a new class of therapy in treating bladder cancers, it is now imperative that all members of the multidisciplinary care team understand both the new data and the best practices to practically apply immuno-oncology strategies to patient care, including methods that proactively plan to manage and mitigate treatment-related toxicities. The annual GU Cancers Symposium is the perfect venue to target educational programming to address knowledge and competence gaps related to the application of these new strategies to real-world clinical practice.
Shifting Paradigms in Bladder Cancer: How Immunotherapeutic Strategies Are Changing Courses of Care will bring together renowned experts for an interactive symposium to discuss the impact of evolving evidence on the use of immuno-oncology agents, including combination strategies, in the management of bladder cancers. This activity will focus on brief didactic presentations followed by “real-world” clinical case scenarios. Challenging cases will be used in conjunction with an audience response system to assess knowledge gaps, practice patterns (“How would you treat this patient in light of the data?”), interpretation of clinical trial data, and changes in practice preferences (pre- vs posttest) among participants. Expert panel discussion will also assess what the near future of bladder cancer treatment may look like based on recent practice-changing evidence and ongoing trials, whose findings are highly anticipated in the field.
This educational program is directed toward oncologists, urologists, and researchers involved in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with bladder cancers are also invited to participate.
Benefits of participating in Shifting Paradigms in Bladder Cancer: How Immunotherapeutic Strategies Are Changing Courses of Care:
- Gain insights into the biology of immunotherapies for managing bladder cancer
- Expand knowledge of ongoing research in biomarkers for immunotherapy in bladder cancer
- Improve competence regarding the integration of checkpoint inhibitors into the management of advanced bladder cancer
- Increase knowledge and competence in the management of treatment-related toxicities associated with immuno-oncology strategies currently used or under investigation for use in the care of patients with bladder cancer
Upon completion of this activity, participants should be able to:
- Explain the mechanistic rationale underlying the use of targeted and immunotherapeutic approaches to manage bladder cancer
- Evaluate pivotal clinical trial results on immunotherapies and evidence concerning emerging biomarkers and combination strategies under evaluation for the treatment of bladder cancer
- Consider practice-changing evidence in the context of multidisciplinary, team-based care approaches for patients with bladder cancer
- Discuss strategies to monitor for, identify, and mitigate the impact of treatment-related toxicities that may occur among patients with bladder cancer
Acknowledgment of Commercial Support
This activity is supported by educational grants from Astellas and Seattle Genetics, Genentech and Merck Sharp & Dohme Corp.
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT
You must be logged in to PER to register for this meeting
Or Register for PER now